Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

equire follow-up each year in the United States. At least 3 million of these results are caused by some type of HPV.

Other Information about GARDASIL

In 1995, Merck entered into a license agreement and research collaboration with CSL Limited of Australia relating to technology used in GARDASIL. GARDASIL also is the subject of other third-party licensing agreements.

Merck recently announced that it submitted a supplemental Biologics License Application (sBLA) to the FDA that includes efficacy data showing GARDASIL offers some protection against additional cervical cancer causing HPV types responsible for greater than 10 percent of cervical cancers, data on protection against additional gynecological cancers -- vulvar and vaginal -- and data on immune memory.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no oblig
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:12/1/2008)...ewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (...t , one of the world,s leading medical journals, r...egulator, experimental compound tasimelteon (VEC-1...titled "Melatonin agonist tasimelteon (VEC-162) fo...andomised controlled multicentre trials." Results ...
(Date:12/1/2008)...swire/ -- Roche announced today that a,comparativ...ived pain and,discomfort associated with blood gl...toring systems and lancing devices were deemed lea...ll, the ACCU-CHEK Aviva and ACCU-CHEK Compact,Plu...EK Multiclix, ACCU-CHEK,Softclix and ACCU-CHEK So...
(Date:12/1/2008)...he best policy , , ROCHESTER, Minn., Dec. ... Clinic finds the use of the drug therapy etanerce... acute inflammation of the liver caused by excessi...y are published in the December issue of Gastroen... , VIDEO ALERT: Additional audio and video res...
(Date:12/1/2008)...d for Tuesday, December 9 at 11:00 am ET to Discus...H SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-Firs... SNSS ), a biopharmaceutical company focused on th...y therapeutics, today announced new data from its ...L) will be presented during the 50th American Soci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 1ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 2ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 3Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 1Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 2Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 1Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 2Scientists unveil mechanism for up and down in plants 5605 1Scientists unveil mechanism for up and down in plants 5605 2
...etary DNA delivery technology enables sustained,In...es,atherosclerosis progression in mouse model of h..., 2007 - Research conducted,at Cleveland Clinic an...ology,s 58th Annual Scientific Session showed that...inflammatory protein,interferon-beta (IFN-beta) us...
...oadministered with statins for only five weeks at,...hieved with,statins alone, with similarly favorabl... and CARLSBAD, Calif., March 26, 2007,/PRNewswire-... new,results from its Phase 2 clinical trial of IS...day at the of Cardiology,Annual Scientific Session...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:12/2/2008)...N, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Ch..." or "the Company") (Nasdaq: CSKI ), a leading,...over-the-counter drugs in,the People,s Republic o...Stanley) Hao was appointed Chief Financial Officer...,s Board of Directors. He replaces Yu-kun Zhang, ...
(Date:12/2/2008)...BURGH, Dec. 2 Mylan Inc....ubsidiary, Mylan Pharmaceuticals Inc., have entere...aceuticals Corp., Novartis,Corp. and Novartis Int...neric,version of Novartis, Femara(R). , My...ted: "We are very,pleased to have reached this ag...
(Date:12/2/2008)...NVILLE, Calif., Dec. 2 In response...n A Toxicity, Frequent Respiratory Infections, and...ovember 11th by 16 well known supplement experts, ... oil products pose no threat or compromise to cons...solutions that are low in natural Vitamin A. Accor...
(Date:12/2/2008)... SPEAK to collect and dissemin... Bellevue, Wash. (PRWEB) December ...ced the launch of a new initiative to focus public...eness . The official kick-off of SPEAK will occur ...acists (ASHP) 2008 Midyear Clinical Meeting, to be...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2
...ave limited benefit in the first-line treatment of...// according to a report in the April issue of Arc...rnals. However, a second report in the same issue ...may be effective in patients with another ulcer-ca...
...n (FDA) is alerting consumers to possible serious ...aminated with a deadly bacterium, Clostridium botu...lly fatal illness. The olives are made by Charlie ... and are being recalled by the manufacturer. No il...
...for liver cancer, says a US study. Using DNA isol... researchers at Columbia University's Mailman Scho...rly detection of liver cancer, says the study publ...of Clinical Cancer Research. The scientists exami...
...ke is an effective way of identifying prostate can...teoporosis, according to a research.// Researcher... Barcelona, Spain, looked at a cross-section of 37...t were receiving androgen-deprivation therapy (ADT...
Other Medicine News:Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 2Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 3Health News:FDA Urgently Warns Consumers About Health Risks of Potentially Contaminated Olives 2Health News:Blood DNA Predicts Liver Cancer Early 2Health News:Measuring Calcium Intake Help to Identify Osteoporosis in Prostate Cancer Patient 2
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products: